Molecular Predictors of Response to Trastuzumab and Lapatinib in Breast Cancer

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2009 Dec 23

PMID 20027191

Citations 80

Authors

Francisco J Esteva

Dihua Yu

Mien-Chie Hung

Gabriel N Hortobagyi

Affiliations

Soon will be listed here.

Abstract

Trastuzumab is a monoclonal antibody directed against the human EGFR2 (HER2) protein that has been shown to improve survival in patients with HER2-positive breast cancer. Lapatinib is an oral small-molecule tyrosine kinase inhibitor directed against EGFR and HER2. Lapatinib therapy was shown to prolong the time to progression and increase the rate of response to capecitabine in patients who had received anthracycline-based and taxane-based chemotherapy, and whose tumors had progressed on trastuzumab. HER2 status, either gene copy number or the protein expression level, is the best predictive marker available for assessing response to trastuzumab and lapatinib. Whether the power of this predictive marker is the same in advanced and early-stage cancers is unknown. There is great interest in developing diagnostic tests that predict which patients are more likely to benefit from specific HER2-directed therapies. Novel therapeutics that will overcome resistance to trastuzumab and lapatinib are under intense clinical development. In the future, it will be important to characterize mechanisms of resistance in metastatic tumors to determine which novel targeted therapy will be most appropriate for individual patients.

Citing Articles

Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.

Degirmenci M, Diniz G, Kahraman D, Sahbazlar M, Koral L, Varol U Breast Cancer (Dove Med Press). 2024; 16:645-655.

PMID: 39355199 PMC: 11444060. DOI: 10.2147/BCTT.S470570.

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.

Esteva F, Katz E JCO Oncol Pract. 2024; 20(8):1046-1054.

PMID: 38471052 PMC: 11368165. DOI: 10.1200/OP.23.00563.

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Zimmerman B, Esteva F Cancers (Basel). 2024; 16(4).

PMID: 38398191 PMC: 10887217. DOI: 10.3390/cancers16040800.

A D-Shaped Polymer Optical Fiber Surface Plasmon Resonance Biosensor for Breast Cancer Detection Applications.

Wu X, Wang Y, Zhang J, Zhang Y, Rao X, Chen C Biosensors (Basel). 2024; 14(1).

PMID: 38248392 PMC: 10813458. DOI: 10.3390/bios14010015.

A new paradigm for classifying and treating HER2-positive breast cancer.

He X, Yeung S, Esteva F Cancer Rep (Hoboken). 2023; 6(8):e1841.

PMID: 37254964 PMC: 10432420. DOI: 10.1002/cnr2.1841.

References

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

Nahta R, Yuan L, Du Y, Esteva F . Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007; 6(2):667-74. DOI: 10.1158/1535-7163.MCT-06-0423. View

Paik S, Kim C, Wolmark N . HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008; 358(13):1409-11. DOI: 10.1056/NEJMc0801440. View

Burstein H, Storniolo A, Franco S, Forster J, Stein S, Rubin S . A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008; 19(6):1068-74. DOI: 10.1093/annonc/mdm601. View

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Sarup J, Johnson R, King K, Fendly B, Lipari M, Napier M . Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1991; 1(2):72-82. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Finkle D, Quan Z, Asghari V, Kloss J, Ghaboosi N, Mai E . HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res. 2004; 10(7):2499-511. DOI: 10.1158/1078-0432.ccr-03-0448. View

10.

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

11.

DiGiovanna M, Stern D, Edgerton S, Broadwater G, Dressler L, Budman D . Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008; 26(14):2364-72. PMC: 6589994. DOI: 10.1200/JCO.2007.13.6580. View

12.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

13.

Adams C, Allison D, Flagella K, Presta L, Clarke J, Dybdal N . Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2005; 55(6):717-27. PMC: 11030689. DOI: 10.1007/s00262-005-0058-x. View

14.

Rotin D, Pinchasi D, Ullrich A, Schlessinger J, Lax I . Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J Biol Chem. 1992; 267(12):8056-63. View

15.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

16.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J . Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3):1170-5. DOI: 10.1158/0008-5472.CAN-06-2101. View

17.

Lu C, Wyszomierski S, Tseng L, Sun M, Lan K, Neal C . Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007; 13(19):5883-8. DOI: 10.1158/1078-0432.CCR-06-2837. View

18.

Pegram M, Pienkowski T, Northfelt D, Eiermann W, Patel R, Fumoleau P . Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004; 96(10):759-69. DOI: 10.1093/jnci/djh133. View

19.

Gong Y, Sweet W, Duh Y, Greenfield L, Fang Y, Zhao J . Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol. 2009; 131(4):490-7. DOI: 10.1309/AJCPI00TVGIGYXAA. View

20.

Di Fiore P, PIERCE J, Fleming T, Hazan R, Ullrich A, King C . Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987; 51(6):1063-70. DOI: 10.1016/0092-8674(87)90592-7. View